Overview Financials News + Filings Key Docs Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation
|
Anzu Special Acquisition Corp I
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/10/2023 |
8-K
| Quarterly results |
10/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failur...
Docs:
|
"Second Amended and Restated Certificate of Incorporation of the Company",
"Amended and Restated Bylaws of the Company",
"Certificate of Designation of Series A Preferred Stock of the Company",
"Amendment to Letter Agreement, by and among Anzu, the Sponsor and Anzu’s officers and directors",
"Amended and Restated Registration Rights Agreement, by and among Anzu Special Acquisition Corp I, Anzu SPAC GP I LLC and certain stockholders",
"Amendment to Letter Agreement, by and among Anzu, the Sponsor and Anzu’s officers and directors",
"Envoy Medical, Inc. Equity Incentive Plan",
"Envoy Medical, Inc. Employee Stock Purchase Plan",
"Amendment No. 2 to Forward Purchase Agreement",
"List of subsidiaries" |
|
10/03/2023 |
4
| Anzu SPAC GP I LLC (10% Owner) has filed a Form 4 on Envoy Medical, Inc.
Txns:
| Converted 2,490,000 shares
@ $0 Disposed of 490,000 shares
@ $0 Bought 1,000,000 options to buy
@ $10, valued at
$10M
Acquired 2,500,000 options to buy
@ $0 Disposed/sold 5,510,000 options to buy
@ $0 Disposed of 2,500,000 options to buy
@ $0 Converted 2,490,000 options to buy
@ $0 |
|
10/03/2023 |
4
| Huskins Priya Cherian (Director) has filed a Form 4 on Envoy Medical, Inc.
Txns:
| Converted 25,000 shares
@ $0 Converted 25,000 options to buy
@ $0 |
|
10/03/2023 |
4
| Kantor Susan (Director) has filed a Form 4 on Envoy Medical, Inc.
Txns:
| Converted 25,000 shares
@ $0 Converted 25,000 options to buy
@ $0 |
|
10/03/2023 |
4
| Hirsch Daniel J. (CFO and Corporate Secretary) has filed a Form 4 on Envoy Medical, Inc.
Txns:
| Converted 25,000 shares
@ $0 Converted 25,000 options to buy
@ $0 |
|
10/03/2023 |
4
| DEWBREY DIANE L (Director) has filed a Form 4 on Envoy Medical, Inc.
Txns:
| Converted 25,000 shares
@ $0 Converted 25,000 options to buy
@ $0 |
|
10/03/2023 |
4
| TAYLOR GLEN A (10% Owner) has filed a Form 4 on Envoy Medical, Inc.
Txns:
| Converted 1,000,000 options to buy
@ $10, valued at
$10M
Converted 869,565 preferred shares
@ $10, valued at
$8.7M
|
|
09/29/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
09/29/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
09/29/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
09/29/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
09/29/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
09/29/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
09/29/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
09/27/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits &...
Docs:
|
"Anzu Special Acquisition Corp I Stockholders Approve Business Combination with Envoy Medical Corporation Tampa, Florida — September 27, 2023 — Anzu Special Acquisition Corp I , announced today that its stockholders voted to approve the Business Combination Agreement with Envoy Medical Corporation , and the transactions contemplated thereby at the Company’ s special meeting of stockholders held on September 27, 2023 . Pursuant to the Business Combination Agreement, Merger Sub will merge with and into Envoy, with Envoy surviving the merger as a wholly owned subsidiary of the Company . Following the closing of the Merger , the Company will be renamed “Envoy Medical, Inc.”, which is referred to herein as “New Envoy.” Over 99% of the votes cast at the Special Meeting were cast in favor of the a..." |
|
08/24/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/04/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
06/30/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/15/2023 |
S-4
| Form S-4 - Registration of securities, business combinations: |
04/18/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
04/18/2023 |
8-K
| Quarterly results |
04/03/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
04/03/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
04/03/2023 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review  ... |
03/31/2023 |
4
| BARCLAYS PLC (10% Owner) has filed a Form 4 on Anzu Special Acquisition Corp I |
03/31/2023 |
3
| BARCLAYS PLC (10% Owner) has filed a Form 3 on Anzu Special Acquisition Corp I |
03/13/2023 |
3
| Atlas Merchant Capital LLC (10% Owner) has filed a Form 3 on Anzu Special Acquisition Corp I |
03/02/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
02/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
02/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data
Docs:
|
"EXTENSION SUPPORT AGREEMENT This EXTENSION SUPPORT AGREEMENT , dated as of [●], 2023 is made by and between Anzu Special Acquisition Corp I, a Delaware corporation , Anzu SPAC GP I LLC, a Delaware limited liability company , and the undersigned holders . WHEREAS, the Sponsor currently holds 10,500,000 shares of Class B common stock, par value $0.0001 per share, of Anzu , which Sponsor Shares shall convert automatically into shares of Class A common stock, par value $0.0001 per share, of Anzu , at the time of the Initial Business Combination ; WHEREAS, Anzu has entered into a letter of intent regarding an Initial Business Combination with Envoy Medical Corporation , a U.S.-based medical device company that has developed and is in early clinical testing of an implanted device that has ..." |
|
02/22/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
|
|
|